{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:00:24Z","timestamp":1789945224554,"version":"4.0.1"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"DOI":"10.1186\/s40842-026-00338-9","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:02:54Z","timestamp":1789941774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Type 1 diabetes and cardiovascular medicine"],"prefix":"10.1186","volume":"12","author":[{"given":"Alicia J.","family":"Jenkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Hemphill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Sindone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali R.","family":"Gnanenthiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick S. R.","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"338_CR1","doi-asserted-by":"publisher","first-page":"112277","DOI":"10.1016\/j.diabres.2025.112277","volume":"225","author":"GD Ogle","year":"2025","unstructured":"Ogle GD, Wang F, Haynes A, Gregory GA, King TW, Deng K, et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Res Clin Pract. 2025;225:112277. https:\/\/doi.org\/10.1016\/j.diabres.2025.112277.","journal-title":"Diabetes Res Clin Pract"},{"key":"338_CR2","unstructured":"Type 1 Diabetes Index [cited. 2026 June 16]; Available from: https:\/\/www.t1dindex.org\/"},{"issue":"3","key":"338_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","volume":"71","author":"TH Marwick","year":"2018","unstructured":"Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. J Am Coll Cardiol. 2018;71(3):339\u201351. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.019.","journal-title":"J Am Coll Cardiol"},{"issue":"10146","key":"338_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/s0140-6736(18)31506-x","volume":"392","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Sattar N, Franz\u00e9n S, Rawshani A, Hattersley AT, Svensson AM, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477\u201386. https:\/\/doi.org\/10.1016\/s0140-6736(18)31506-x.","journal-title":"Lancet"},{"issue":"4","key":"338_CR5","doi-asserted-by":"publisher","first-page":"107833","DOI":"10.1016\/j.jdiacomp.2020.107833","volume":"35","author":"X Cai","year":"2021","unstructured":"Cai X, Li J, Cai W, Chen C, Ma J, Xie Z, et al. Meta-analysis of type 1 diabetes mellitus and risk of cardiovascular disease. J Diabetes Complications. 2021;35(4):107833. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107833.","journal-title":"J Diabetes Complications"},{"key":"338_CR6","doi-asserted-by":"publisher","first-page":"110805","DOI":"10.1016\/j.diabres.2023.110805","volume":"202","author":"M Haji","year":"2023","unstructured":"Haji M, Erqou S, Fonarow GC, Echouffo-Tcheugui JB. Type 1 diabetes and risk of heart failure: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2023;202:110805. https:\/\/doi.org\/10.1016\/j.diabres.2023.110805.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"338_CR7","doi-asserted-by":"publisher","first-page":"e000602","DOI":"10.1136\/bmjdrc-2018-000602","volume":"7","author":"AF \u00d3lafsd\u00f3ttir","year":"2019","unstructured":"\u00d3lafsd\u00f3ttir AF, Svensson AM, Pivodic A, Gudbj\u00f6rnsdottir S, Nystr\u00f6m T, Wedel H, et al. Excess risk of lower extremity amputations in people with type 1 diabetes compared with the general population: amputations and type 1 diabetes. BMJ Open Diabetes Res Care. 2019;7(1):e000602. https:\/\/doi.org\/10.1136\/bmjdrc-2018-000602.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"338_CR8","doi-asserted-by":"publisher","unstructured":"Colom C, Rull A, Sanchez-Quesada JL, P\u00e9rez A. Cardiovascular Disease in Type 1 Diabetes Mellitus: Epidemiology and Management of Cardiovascular Risk. J Clin Med. 2021;10(8). https:\/\/doi.org\/10.3390\/jcm10081798.","DOI":"10.3390\/jcm10081798"},{"issue":"1","key":"338_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/xce.0000000000000167","volume":"8","author":"H Sharma","year":"2019","unstructured":"Sharma H, Lencioni M, Narendran P. Cardiovascular disease in type 1 diabetes. Cardiovasc Endocrinol Metab. 2019;8(1):28\u201334. https:\/\/doi.org\/10.1097\/xce.0000000000000167.","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"38","key":"338_CR10","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1093\/eurheartj\/ehaf304","volume":"46","author":"Y Wei","year":"2025","unstructured":"Wei Y, Andersson T, Tuomi T, Nystr\u00f6m T, Carlsson S. Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality. Eur Heart J. 2025;46(38):3776\u201386. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf304.","journal-title":"Eur Heart J"},{"issue":"10","key":"338_CR11","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/s2213-8587(25)00165-2","volume":"13","author":"V Patsoukaki","year":"2025","unstructured":"Patsoukaki V, Lind L, Lampa E, Radhi S, Eeg-Olofsson K, Eliasson B, et al. Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data. Lancet Diabetes Endocrinol. 2025;13(10):848\u201362. https:\/\/doi.org\/10.1016\/s2213-8587(25)00165-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"338_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/xce.0000000000000169","volume":"8","author":"A Jenkins","year":"2019","unstructured":"Jenkins A, Januszewski A, O\u2019Neal D. The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it. Cardiovasc Endocrinol Metab. 2019;8(1):14\u201327. https:\/\/doi.org\/10.1097\/xce.0000000000000169.","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"7","key":"338_CR13","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.2337\/diabetes.51.7.2282","volume":"51","author":"EJ Wiltshire","year":"2002","unstructured":"Wiltshire EJ, Gent R, Hirte C, Pena A, Thomas DW, Couper JJ. Endothelial dysfunction relates to folate status in children and adolescents with type 1 diabetes. Diabetes. 2002;51(7):2282\u20136. https:\/\/doi.org\/10.2337\/diabetes.51.7.2282.","journal-title":"Diabetes"},{"issue":"12","key":"338_CR14","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jdiacomp.2017.08.007","volume":"31","author":"PZ Benitez-Aguirre","year":"2017","unstructured":"Benitez-Aguirre PZ, Januszewski AS, Cho YH, Craig ME, Jenkins AJ, Donaghue KC. Early changes of arterial elasticity in Type 1 diabetes with microvascular complications - A cross-sectional study from childhood to adulthood. J Diabetes Complications. 2017;31(12):1674\u201380. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.08.007.","journal-title":"J Diabetes Complications"},{"issue":"3","key":"338_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/pedi.12557","volume":"19","author":"C Lilje","year":"2018","unstructured":"Lilje C, Cronan JC, Schwartzenburg EJ, Owers EM, Clesi P, Gomez R, et al. Intima-media thickness at different arterial segments in pediatric type 1 diabetes patients and its relationship with advanced glycation end products. Pediatr Diabetes. 2018;19(3):450\u20136. https:\/\/doi.org\/10.1111\/pedi.12557.","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"338_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11892-013-0379-7","volume":"13","author":"JK Snell-Bergeon","year":"2013","unstructured":"Snell-Bergeon JK, Budoff MJ, Hokanson JE. Vascular calcification in diabetes: mechanisms and implications. Curr Diab Rep. 2013;13(3):391\u2013402. https:\/\/doi.org\/10.1007\/s11892-013-0379-7.","journal-title":"Curr Diab Rep"},{"issue":"11","key":"338_CR17","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1253\/circj.cj-14-1080","volume":"78","author":"C Riehle","year":"2014","unstructured":"Riehle C, Abel ED. Insulin regulation of myocardial autophagy. Circ J. 2014;78(11):2569\u201376. https:\/\/doi.org\/10.1253\/circj.cj-14-1080.","journal-title":"Circ J"},{"issue":"1","key":"338_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.diabres.2004.09.004","volume":"67","author":"N Ahmed","year":"2005","unstructured":"Ahmed N. Advanced glycation endproducts\u2013role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3\u201321. https:\/\/doi.org\/10.1016\/j.diabres.2004.09.004.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"338_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1161\/circulationaha.118.036068","volume":"139","author":"GR Sousa","year":"2019","unstructured":"Sousa GR, Pober D, Galderisi A, Lv H, Yu L, Pereira AC, et al. Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus. Circulation. 2019;139(6):730\u201343. https:\/\/doi.org\/10.1161\/circulationaha.118.036068.","journal-title":"Circulation"},{"issue":"3","key":"338_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","volume":"142","author":"K Huynh","year":"2014","unstructured":"Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014;142(3):375\u2013415. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.01.003.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"338_CR21","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2337\/dc12-2147","volume":"36","author":"S Paolillo","year":"2013","unstructured":"Paolillo S, Rengo G, Pagano G, Pellegrino T, Savarese G, Femminella GD, et al. Impact of diabetes on cardiac sympathetic innervation in patients with heart failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study. Diabetes Care. 2013;36(8):2395\u2013401. https:\/\/doi.org\/10.2337\/dc12-2147.","journal-title":"Diabetes Care"},{"issue":"26","key":"338_CR22","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.2174\/138161207781662984","volume":"13","author":"KA Connelly","year":"2007","unstructured":"Connelly KA, Boyle AJ, Kelly DJ. Angiotensin II and the cardiac complications of diabetes mellitus. Curr Pharm Des. 2007;13(26):2721\u20139. https:\/\/doi.org\/10.2174\/138161207781662984.","journal-title":"Curr Pharm Des"},{"issue":"5","key":"338_CR23","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2337\/dbi19-0026","volume":"69","author":"JM Gregory","year":"2020","unstructured":"Gregory JM, Cherrington AD, Moore DJ. The Peripheral Peril: Injected Insulin Induces Insulin Insensitivity in Type 1 Diabetes. Diabetes. 2020;69(5):837\u201347. https:\/\/doi.org\/10.2337\/dbi19-0026.","journal-title":"Diabetes"},{"issue":"3","key":"338_CR24","doi-asserted-by":"publisher","first-page":"109268","DOI":"10.1016\/j.jdiacomp.2026.109268","volume":"40","author":"NSR Lan","year":"2026","unstructured":"Lan NSR, Fegan PG, Jenkins AJ. High risk, low evidence: Need for more research on lipid-lowering therapies for people with type 1 diabetes. J Diabetes Complications. 2026;40(3):109268. https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109268.","journal-title":"J Diabetes Complications"},{"key":"338_CR25","doi-asserted-by":"publisher","unstructured":"Christou MA, Christou PA, Kyriakopoulos C, Christou GA, Tigas S. Effects of Hypoglycemia on Cardiovascular Function in Patients with Diabetes. Int J Mol Sci. 2023;24(11). https:\/\/doi.org\/10.3390\/ijms24119357.","DOI":"10.3390\/ijms24119357"},{"issue":"11","key":"338_CR26","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.2337\/db12-0224","volume":"61","author":"A Ceriello","year":"2012","unstructured":"Ceriello A, Novials A, Ortega E, La Sala L, Pujadas G, Testa R, et al. Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes. 2012;61(11):2993\u20137. https:\/\/doi.org\/10.2337\/db12-0224.","journal-title":"Diabetes"},{"key":"338_CR27","first-page":"27","volume":"129","author":"SR Heller","year":"2002","unstructured":"Heller SR. Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome? Int J Clin Pract Suppl. 2002;129:27\u201332.","journal-title":"Int J Clin Pract Suppl"},{"key":"338_CR28","doi-asserted-by":"publisher","first-page":"h3234","DOI":"10.1136\/bmj.h3234","volume":"350","author":"I Steineck","year":"2015","unstructured":"Steineck I, Cederholm J, Eliasson B, Rawshani A, Eeg-Olofsson K, Svensson AM, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ. 2015;350:h3234. https:\/\/doi.org\/10.1136\/bmj.h3234.","journal-title":"BMJ"},{"key":"338_CR29","doi-asserted-by":"publisher","first-page":"108609","DOI":"10.1016\/j.diabres.2020.108609","volume":"171","author":"A Pease","year":"2021","unstructured":"Pease A, Szwarcbard N, Earnest A, Andrikopoulos S, Wischer N, Zoungas S. Glycaemia and utilisation of technology across the lifespan of adults with type 1 diabetes: Results of the Australian National Diabetes Audit (ANDA). Diabetes Res Clin Pract. 2021;171:108609. https:\/\/doi.org\/10.1016\/j.diabres.2020.108609.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"338_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-018-0726-8","volume":"17","author":"A Pease","year":"2018","unstructured":"Pease A, Earnest A, Ranasinha S, Nanayakkara N, Liew D, Wischer N, et al. Burden of cardiovascular risk factors and disease among patients with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA). Cardiovasc Diabetol. 2018;17(1):77. https:\/\/doi.org\/10.1186\/s12933-018-0726-8.","journal-title":"Cardiovasc Diabetol"},{"key":"338_CR31","doi-asserted-by":"publisher","first-page":"110093","DOI":"10.1016\/j.diabres.2022.110093","volume":"192","author":"MM Nejatian","year":"2022","unstructured":"Nejatian MM, Lan NSR, Yeap BB, Dwivedi G, Fegan PG, Ihdayhid AR. Characteristics and outcomes of patients with type 1 diabetes admitted with acute coronary syndromes. Diabetes Res Clin Pract. 2022;192:110093. https:\/\/doi.org\/10.1016\/j.diabres.2022.110093.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"338_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2337\/dci25-0015","volume":"49","author":"JR Snaith","year":"2026","unstructured":"Snaith JR, Narongkiatikhun P, Bjornstad P, Greenfield JR, Tommerdahl KL. Advancing Type 1 Diabetes Management: Integrating Novel Therapies, Technologies, and Adjunctive Approaches. Diabetes Care. 2026;49(1):7\u201321. https:\/\/doi.org\/10.2337\/dci25-0015.","journal-title":"Diabetes Care"},{"issue":"2","key":"338_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s13300-024-01687-3","volume":"16","author":"JR Greenfield","year":"2025","unstructured":"Greenfield JR, Frampton R, Millard K, Snaith JR. Use of Cardioprotective Adjuncts in Type 1 Diabetes. Diabetes Ther. 2025;16(2):145\u20138. https:\/\/doi.org\/10.1007\/s13300-024-01687-3.","journal-title":"Diabetes Ther"},{"issue":"2","key":"338_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tem.2019.11.007","volume":"31","author":"JR Snaith","year":"2020","unstructured":"Snaith JR, Holmes-Walker DJ, Greenfield JR. Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies? Trends Endocrinol Metab. 2020;31(2):150\u201364. https:\/\/doi.org\/10.1016\/j.tem.2019.11.007.","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"338_CR35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/s2213-8587(17)30194-8","volume":"5","author":"JR Petrie","year":"2017","unstructured":"Petrie JR, Chaturvedi N, Ford I, Brouwers M, Greenlaw N, Tillin T, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597\u2013609. https:\/\/doi.org\/10.1016\/s2213-8587(17)30194-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"338_CR36","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1210\/jc.2017-00781","volume":"102","author":"JJA Anderson","year":"2017","unstructured":"Anderson JJA, Couper JJ, Giles LC, Leggett CE, Gent R, Coppin B, et al. Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial. J Clin Endocrinol Metab. 2017;102(12):4448\u201356. https:\/\/doi.org\/10.1210\/jc.2017-00781.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 7","key":"338_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/dom.15921","volume":"26","author":"YW Kong","year":"2024","unstructured":"Kong YW, Morrison D, Lu JC, Lee MH, Jenkins AJ, O\u2019Neal DN. Continuous ketone monitoring: Exciting implications for clinical practice. Diabetes Obes Metab. 2024;26(Suppl 7):47\u201358. https:\/\/doi.org\/10.1111\/dom.15921.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"338_CR38","doi-asserted-by":"publisher","first-page":"e098457","DOI":"10.1136\/bmjopen-2024-098457","volume":"15","author":"J Ngan","year":"2025","unstructured":"Ngan J, Kong YW, Goad J, Huang MLH, Jenkins A, Vogrin S, et al. Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: the PARTNER study. BMJ Open. 2025;15(5):e098457. https:\/\/doi.org\/10.1136\/bmjopen-2024-098457.","journal-title":"BMJ Open"},{"issue":"1","key":"338_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/15209156251362494","volume":"28","author":"YW Kong","year":"2026","unstructured":"Kong YW, Jones HC, Ngan J, Goad J, Jenkins AJ, Nolan CJ, et al. Preventing Diabetic Ketoacidosis with Continuous Ketone Monitoring: Insights from a Clinical Research Case. Diabetes Technol Ther. 2026;28(1):73\u20137. https:\/\/doi.org\/10.1177\/15209156251362494.","journal-title":"Diabetes Technol Ther"},{"issue":"Supplement1","key":"338_CR40","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.2337\/dc26-S010","volume":"49","author":"10","year":"2026","unstructured":"10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement1):S216\u201345. https:\/\/doi.org\/10.2337\/dc26-S010.","journal-title":"Diabetes Care"},{"key":"338_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/dddt.s3225","volume":"2","author":"G Ryan","year":"2009","unstructured":"Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther. 2009;2:203\u201314. https:\/\/doi.org\/10.2147\/dddt.s3225.","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"338_CR42","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2337\/dc10-0505","volume":"33","author":"HD Margeirsdottir","year":"2010","unstructured":"Margeirsdottir HD, Stensaeth KH, Larsen JR, Brunborg C, Dahl-J\u00f8rgensen K. Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study. Diabetes Care. 2010;33(9):2043\u20138. https:\/\/doi.org\/10.2337\/dc10-0505.","journal-title":"Diabetes Care"},{"issue":"1","key":"338_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3132\/dvdr.2007.009","volume":"4","author":"JR Larsen","year":"2007","unstructured":"Larsen JR, Tsunoda T, Tuzcu EM, Schoenhagen P, Brekke M, Arnesen H, et al. Intracoronary ultrasound examinations reveal significantly more advanced coronary atherosclerosis in people with type 1 diabetes than in age- and sex-matched non-diabetic controls. Diab Vasc Dis Res. 2007;4(1):62\u20135. https:\/\/doi.org\/10.3132\/dvdr.2007.009.","journal-title":"Diab Vasc Dis Res"},{"issue":"6","key":"338_CR44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tem.2020.01.015","volume":"31","author":"B Verg\u00e8s","year":"2020","unstructured":"Verg\u00e8s B. Dyslipidemia in Type 1 Diabetes: AMaskedDanger. Trends Endocrinol Metab. 2020;31(6):422\u201334. https:\/\/doi.org\/10.1016\/j.tem.2020.01.015.","journal-title":"Trends Endocrinol Metab"},{"key":"338_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.10.018","volume":"267","author":"S Ganjali","year":"2017","unstructured":"Ganjali S, Dallinga-Thie GM, Simental-Mend\u00eda LE, Banach M, Pirro M, Sahebkar A. HDL functionality in type 1 diabetes. Atherosclerosis. 2017;267:99\u2013109. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.10.018.","journal-title":"Atherosclerosis"},{"issue":"1","key":"338_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00125-023-06041-z","volume":"67","author":"WE Corpeleijn","year":"2024","unstructured":"Corpeleijn WE, de Waal WJ, Schipper HS, Wiegman A. Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia. Diabetologia. 2024;67(1):19\u201326. https:\/\/doi.org\/10.1007\/s00125-023-06041-z.","journal-title":"Diabetologia"},{"issue":"12","key":"338_CR47","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1007\/s00125-010-1886-6","volume":"53","author":"DM Maahs","year":"2010","unstructured":"Maahs DM, Ogden LG, Dabelea D, Snell-Bergeon JK, Daniels SR, Hamman RF, et al. Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. Diabetologia. 2010;53(12):2518\u201325. https:\/\/doi.org\/10.1007\/s00125-010-1886-6.","journal-title":"Diabetologia"},{"issue":"2","key":"338_CR48","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1194\/jlr.P060657","volume":"57","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Jenkins AJ, Basu A, Stoner JA, Lopes-Virella MF, Klein RL, et al. Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res. 2016;57(2):310\u20137. https:\/\/doi.org\/10.1194\/jlr.P060657.","journal-title":"J Lipid Res"},{"issue":"32","key":"338_CR49","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"key":"338_CR50","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/978-3-031-26681-2_28","volume-title":"Lipoproteins in Diabetes Mellitus","author":"NSR Lan","year":"2023","unstructured":"Lan NSR, Jenkins AJ, Fegan PG. Clinical Care of Lipids in People with Type 1 Diabetes. In: Jenkins AJ, Toth PP, editors. Lipoproteins in Diabetes Mellitus. Cham: Springer International Publishing; 2023. pp. 755\u201378."},{"issue":"7","key":"338_CR51","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.amjcard.2015.07.020","volume":"116","author":"P Bjornstad","year":"2015","unstructured":"Bjornstad P, Eckel RH, Pyle L, Rewers M, Maahs DM, Snell-Bergeon JK. Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus. Am J Cardiol. 2015;116(7):1057\u201362. https:\/\/doi.org\/10.1016\/j.amjcard.2015.07.020.","journal-title":"Am J Cardiol"},{"issue":"42","key":"338_CR52","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van Roeters JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359\u201378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J"},{"issue":"7","key":"338_CR53","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.2337\/dc06-0546","volume":"29","author":"B Kollerits","year":"2006","unstructured":"Kollerits B, Auinger M, Reisig V, K\u00e4stenbauer T, Lingenhel A, Irsigler K, et al. Lipoprotein(a) as a predictor of cardiovascular disease in a prospectively followed cohort of patients with type 1 diabetes. Diabetes Care. 2006;29(7):1661\u20133. https:\/\/doi.org\/10.2337\/dc06-0546.","journal-title":"Diabetes Care"},{"issue":"8","key":"338_CR54","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2337\/dc19-1398","volume":"43","author":"K Littmann","year":"2020","unstructured":"Littmann K, Wodaje T, Alvarsson M, Bottai M, Eriksson M, Parini P, et al. The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes. Diabetes Care. 2020;43(8):1851\u20138. https:\/\/doi.org\/10.2337\/dc19-1398.","journal-title":"Diabetes Care"},{"issue":"6","key":"338_CR55","doi-asserted-by":"publisher","first-page":"996","DOI":"10.2337\/dc15-2450","volume":"39","author":"C Hero","year":"2016","unstructured":"Hero C, Rawshani A, Svensson AM, Franz\u00e9n S, Eliasson B, Eeg-Olofsson K, et al. Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes. Diabetes Care. 2016;39(6):996\u20131003. https:\/\/doi.org\/10.2337\/dc15-2450.","journal-title":"Diabetes Care"},{"issue":"16","key":"338_CR56","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/circulationaha.116.025961","volume":"135","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Eliasson B, Svensson AM, Miftaraj M, et al. Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1. Diabetes Mellitus Circulation. 2017;135(16):1522\u201331. https:\/\/doi.org\/10.1161\/circulationaha.116.025961.","journal-title":"Diabetes Mellitus Circulation"},{"issue":"16","key":"338_CR57","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1161\/circulationaha.118.037454","volume":"139","author":"A Rawshani","year":"2019","unstructured":"Rawshani A, Rawshani A, Sattar N, Franz\u00e9n S, McGuire DK, Eliasson B, et al. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation. 2019;139(16):1900\u201312. https:\/\/doi.org\/10.1161\/circulationaha.118.037454.","journal-title":"Circulation"},{"issue":"9607","key":"338_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s0140-6736(08)60104-x","volume":"371","author":"PM Kearney","year":"2008","unstructured":"Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117\u201325. https:\/\/doi.org\/10.1016\/s0140-6736(08)60104-x.","journal-title":"Lancet"},{"issue":"12","key":"338_CR59","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/s2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350. https:\/\/doi.org\/10.1016\/s2213-8587(17)30313-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"338_CR60","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/s2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618\u201328. https:\/\/doi.org\/10.1016\/s2213-8587(19)30158-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"338_CR61","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.diabet.2018.12.002","volume":"46","author":"NSR Lan","year":"2020","unstructured":"Lan NSR, Yeap BB, Bell DA, Watts GF, Fegan PG. Patients with type 1 diabetes in a tertiary setting do not attain recommended lipid targets. Diabetes Metab. 2020;46(4):339\u201341. https:\/\/doi.org\/10.1016\/j.diabet.2018.12.002.","journal-title":"Diabetes Metab"},{"key":"338_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/imj.70276","author":"NSR Lan","year":"2025","unstructured":"Lan NSR, Ryan C, Rud\u00e9n A, Glasby JRK, Nanayakkara N, Elghattis Y, et al. Enhancing nationwide awareness of cholesterol treatment in type 1 diabetes (ENACT-T1D): an Australian multi-centre survey of patients and clinicians. Intern Med J. 2025. https:\/\/doi.org\/10.1111\/imj.70276.","journal-title":"Intern Med J"},{"issue":"5","key":"338_CR63","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.pcd.2023.07.005","volume":"17","author":"NSR Lan","year":"2023","unstructured":"Lan NSR, Hong RSY, Ryan C, Jenkins AJ, Fegan PG. Patient perceptions of cardiovascular risk, lipid management and statins in type 1 diabetes. Prim Care Diabetes. 2023;17(5):526\u20138. https:\/\/doi.org\/10.1016\/j.pcd.2023.07.005.","journal-title":"Prim Care Diabetes"},{"key":"338_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.11.016","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026. https:\/\/doi.org\/10.1016\/j.jacc.2025.11.016.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"338_CR65","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"12","key":"338_CR66","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/hjh.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/hjh.0000000000003480.","journal-title":"J Hypertens"},{"issue":"6","key":"338_CR67","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/hypertensionaha.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334\u201357. https:\/\/doi.org\/10.1161\/hypertensionaha.120.15026.","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"338_CR68","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1097\/01.hjh.0000837276.72944.7b","volume":"40","author":"T Chalakova","year":"2022","unstructured":"Chalakova T, Tsochev K, Yotov Y, Bocheva Y, Valchev G, Usheva N, et al. ARTERIAL HYPERTENSION IN PATIENTS WITH LONG DURATION TYPE 1 DIABETES MELLITUS. J Hypertens. 2022;40(Suppl 1):e184. https:\/\/doi.org\/10.1097\/01.hjh.0000837276.72944.7b.","journal-title":"J Hypertens"},{"issue":"6","key":"338_CR69","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00592-023-02057-4","volume":"60","author":"S James","year":"2023","unstructured":"James S, Perry L, Lowe J, Harris M, Colman PG, Craig ME. Blood pressure in adolescents and young adults with type 1 diabetes: data from the Australasian Diabetes Data Network registry. Acta Diabetol. 2023;60(6):797\u2013803. https:\/\/doi.org\/10.1007\/s00592-023-02057-4.","journal-title":"Acta Diabetol"},{"issue":"7","key":"338_CR70","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/bf00404089","volume":"33","author":"K N\u00f8rgaard","year":"1990","unstructured":"N\u00f8rgaard K, Feldt-Rasmussen B, Borch-Johnsen K, Saelan H, Deckert T. Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1990;33(7):407\u201310. https:\/\/doi.org\/10.1007\/bf00404089.","journal-title":"Diabetologia"},{"issue":"3","key":"338_CR71","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2337\/dc13-2023","volume":"37","author":"R Lithovius","year":"2014","unstructured":"Lithovius R, Harjutsalo V, Forsblom C, Saraheimo M, Groop PH. Antihypertensive treatment and resistant hypertension in patients with type 1 diabetes by stages of diabetic nephropathy. Diabetes Care. 2014;37(3):709\u201317. https:\/\/doi.org\/10.2337\/dc13-2023.","journal-title":"Diabetes Care"},{"issue":"4","key":"338_CR72","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/strokeaha.121.035851","volume":"53","author":"IJ McGurgan","year":"2022","unstructured":"McGurgan IJ, Kelly PJ, Turan TN, Rothwell PM. Long-Term Secondary Prevention: Management of Blood Pressure After a Transient Ischemic Attack or Stroke. Stroke. 2022;53(4):1085\u2013103. https:\/\/doi.org\/10.1161\/strokeaha.121.035851.","journal-title":"Stroke"},{"key":"338_CR73","doi-asserted-by":"publisher","first-page":"111794","DOI":"10.1016\/j.diabres.2024.111794","volume":"215","author":"R Lithovius","year":"2024","unstructured":"Lithovius R, Mutter S, Parente EB, Harjutsalo V, Groop PH. Adherence to cardio-protective medications and cardiovascular disease in adults with type 1 diabetes. Diabetes Res Clin Pract. 2024;215:111794. https:\/\/doi.org\/10.1016\/j.diabres.2024.111794.","journal-title":"Diabetes Res Clin Pract"},{"issue":"20","key":"338_CR74","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/nejm199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456\u201362. https:\/\/doi.org\/10.1056\/nejm199311113292004.","journal-title":"N Engl J Med"},{"issue":"5","key":"338_CR75","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s0002-9343(99)80226-5","volume":"99","author":"LM Laffel","year":"1995","unstructured":"Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995;99(5):497\u2013504. https:\/\/doi.org\/10.1016\/s0002-9343(99)80226-5.","journal-title":"Am J Med"},{"issue":"4","key":"338_CR76","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","volume":"271","author":"G Viberti","year":"1994","unstructured":"Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271(4):275\u20139.","journal-title":"JAMA"},{"issue":"12","key":"338_CR77","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2337\/diacare.23.12.1725","volume":"23","author":"L Tarnow","year":"2000","unstructured":"Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2000;23(12):1725\u201330. https:\/\/doi.org\/10.2337\/diacare.23.12.1725.","journal-title":"Diabetes Care"},{"issue":"10","key":"338_CR78","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000249","volume":"82","author":"M Writing Committee","year":"2025","unstructured":"Writing Committee M, Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10):e212\u2013316. https:\/\/doi.org\/10.1161\/HYP.0000000000000249.","journal-title":"Hypertension"},{"issue":"12","key":"338_CR79","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/hjh.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/hjh.0000000000003480.","journal-title":"J Hypertens"},{"issue":"1","key":"338_CR80","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2337\/cd22-as01","volume":"40","author":"A American Diabetes","year":"2022","unstructured":"American Diabetes A. Standards of Medical Care in Diabetes\u20142022 Abridged for Primary Care Providers. Clin Diabetes. 2022;40(1):10\u201338. https:\/\/doi.org\/10.2337\/cd22-as01.","journal-title":"Clin Diabetes"},{"issue":"5s","key":"338_CR81","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5s):S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"issue":"4","key":"338_CR82","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ekir.2022.01.004","volume":"7","author":"D Banerjee","year":"2022","unstructured":"Banerjee D, Winocour P, Chowdhury TA, De P, Wahba M, Montero R, et al. Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021. Kidney Int Rep. 2022;7(4):681\u20137. https:\/\/doi.org\/10.1016\/j.ekir.2022.01.004.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"338_CR83","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2337\/diacare.26.3.911","volume":"26","author":"P Hovind","year":"2003","unstructured":"Hovind P, Rossing P, Tarnow L, Parving H-H. Smoking and Progression of Diabetic Nephropathy in Type 1 Diabetes. Diabetes Care. 2003;26(3):911\u20136. https:\/\/doi.org\/10.2337\/diacare.26.3.911.","journal-title":"Diabetes Care"},{"issue":"2","key":"338_CR84","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1001\/jama.280.2.140","volume":"280","author":"JQ Purnell","year":"1998","unstructured":"Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control Complications Trial Jama. 1998;280(2):140\u20136. https:\/\/doi.org\/10.1001\/jama.280.2.140.","journal-title":"Diabetes Control Complications Trial Jama"},{"issue":"11","key":"338_CR85","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2337\/dc16-1728","volume":"39","author":"SR Colberg","year":"2016","unstructured":"Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical Activity\/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065\u201379. https:\/\/doi.org\/10.2337\/dc16-1728.","journal-title":"Diabetes Care"},{"key":"338_CR86","doi-asserted-by":"publisher","unstructured":"Suckling RJ, He FJ, Macgregor GA. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 2010;12Cd006763. https:\/\/doi.org\/10.1002\/14651858.CD006763.pub2.","DOI":"10.1002\/14651858.CD006763.pub2"},{"key":"338_CR87","doi-asserted-by":"publisher","unstructured":"Hodson EM, Cooper TE. Altered dietary salt intake for preventing diabetic kidney disease and its progression. Cochrane Database Syst Reviews. 2023;1. https:\/\/doi.org\/10.1002\/14651858.CD006763.pub3.","DOI":"10.1002\/14651858.CD006763.pub3"},{"issue":"Supplement1","key":"338_CR88","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","volume":"48","author":"ADAPP Committee","year":"2024","unstructured":"Committee ADAPP. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142025. Diabetes Care. 2024;48(Supplement1):S239\u201351. https:\/\/doi.org\/10.2337\/dc25-S011.","journal-title":"Diabetes Care"},{"issue":"7","key":"338_CR89","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/s2213-8587(15)00040-6","volume":"3","author":"K Matsushita","year":"2015","unstructured":"Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514\u201325. https:\/\/doi.org\/10.1016\/s2213-8587(15)00040-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"338_CR90","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00125-018-4564-8","volume":"61","author":"FJ Jansson","year":"2018","unstructured":"Jansson FJ, Forsblom C, Harjutsalo V, Thorn LM, Wad\u00e9n J, Elonen N, et al. Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes: the FinnDiane Study. Diabetologia. 2018;61(5):1203\u201311. https:\/\/doi.org\/10.1007\/s00125-018-4564-8.","journal-title":"Diabetologia"},{"issue":"1","key":"338_CR91","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cardfail.2025.05.021","volume":"32","author":"JT Ha","year":"2026","unstructured":"Ha JT, Fletcher RA, Arnott C, Jun M, Kotwal SS, Perkovic V, et al. Albuminuria, Kidney Function and Heart Failure Risk in Type 2 Diabetes: Participant-level Pooled Analysis from the CANVAS Program and CREDENCE Trial. J Card Fail. 2026;32(1):151\u20136. https:\/\/doi.org\/10.1016\/j.cardfail.2025.05.021.","journal-title":"J Card Fail"},{"issue":"3","key":"338_CR92","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.ajkd.2023.07.023","volume":"83","author":"JT Ha","year":"2024","unstructured":"Ha JT, Freedman SB, Kelly DM, Neuen BL, Perkovic V, Jun M, et al. Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis. Am J Kidney Dis. 2024;83(3):350\u2013e91. https:\/\/doi.org\/10.1053\/j.ajkd.2023.07.023.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"338_CR93","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2337\/db08-1543","volume":"58","author":"PH Groop","year":"2009","unstructured":"Groop PH, Thomas MC, Moran JL, Wad\u00e8n J, Thorn LM, M\u00e4kinen VP, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7):1651\u20138. https:\/\/doi.org\/10.2337\/db08-1543.","journal-title":"Diabetes"},{"issue":"9731","key":"338_CR94","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/s0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073\u201381. https:\/\/doi.org\/10.1016\/s0140-6736(10)60674-5.","journal-title":"Lancet"},{"issue":"12","key":"338_CR95","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390. https:\/\/doi.org\/10.2337\/dci22-0027.","journal-title":"Diabetes Care"},{"issue":"5s","key":"338_CR96","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","year":"2022","unstructured":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5s):S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"issue":"5","key":"338_CR97","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/s0272-6386(05)80003-4","volume":"37","author":"G Jerums","year":"2001","unstructured":"Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis. 2001;37(5):890\u20139. https:\/\/doi.org\/10.1016\/s0272-6386(05)80003-4.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"338_CR98","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/s2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7(2):128\u201339. https:\/\/doi.org\/10.1016\/s2213-8587(18)30314-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"338_CR99","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ki.2013.444","volume":"85","author":"A Levin","year":"2014","unstructured":"Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1):49\u201361. https:\/\/doi.org\/10.1038\/ki.2013.444.","journal-title":"Kidney Int"},{"issue":"1","key":"338_CR100","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.kint.2025.10.004","volume":"109","author":"N Tangri","year":"2026","unstructured":"Tangri N, Neuen BL, Cherney DZ, Tuttle KR, Perkovic V. From progression to remission: a new paradigm for success in chronic kidney disease. Kidney Int. 2026;109(1):17\u201321. https:\/\/doi.org\/10.1016\/j.kint.2025.10.004.","journal-title":"Kidney Int"},{"issue":"26","key":"338_CR101","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, et al. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020;382(26):2493\u2013503. https:\/\/doi.org\/10.1056\/NEJMoa1916624.","journal-title":"N Engl J Med"},{"issue":"12","key":"338_CR102","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1016\/j.ekir.2024.09.010","volume":"9","author":"CG Poulsen","year":"2024","unstructured":"Poulsen CG, Jesse K, Carstensen B, Frimodt-M\u00f8ller M, Hansen TW, Persson F, et al. Prognosis for Type 1 Diabetes with Diabetic Nephropathy between 2000 and 2020 - Changes in Kidney Function Decline Over Time and Development of Cardiovascular Disease, Kidney Failure, and Mortality. Kidney Int Rep. 2024;9(12):3403\u201313. https:\/\/doi.org\/10.1016\/j.ekir.2024.09.010.","journal-title":"Kidney Int Rep"},{"key":"338_CR103","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70640","author":"ML Caramori","year":"2026","unstructured":"Caramori ML, Repetto E, Perkins C, Pandey A, Rossing P. Cardio-Kidney-Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Obes Metab. 2026. https:\/\/doi.org\/10.1111\/dom.70640.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"338_CR104","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa2512854","volume":"394","author":"HJL Heerspink","year":"2026","unstructured":"Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Groop PH, Ji L, et al. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med. 2026;394(10):947\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2512854.","journal-title":"N Engl J Med"},{"issue":"5","key":"338_CR105","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1681\/asn.0000000540","volume":"36","author":"VS Sridhar","year":"2025","unstructured":"Sridhar VS, Odutayo A, Garg S, Danne T, Doria A, Mauer M, et al. Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD. J Am Soc Nephrol. 2025;36(5):890\u2013900. https:\/\/doi.org\/10.1681\/asn.0000000540.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"338_CR106","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"9","year":"2024","unstructured":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158\u201378. https:\/\/doi.org\/10.2337\/dc24-S009.","journal-title":"Diabetes Care"},{"issue":"2","key":"338_CR107","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","volume":"54","author":"TM Davis","year":"2011","unstructured":"Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011;54(2):280\u201390. https:\/\/doi.org\/10.1007\/s00125-010-1951-1.","journal-title":"Diabetologia"},{"key":"338_CR108","doi-asserted-by":"publisher","first-page":"100469","DOI":"10.1016\/j.lanepe.2022.100469","volume":"21","author":"S Hallstr\u00f6m","year":"2022","unstructured":"Hallstr\u00f6m S, Wijkman MO, Ludvigsson J, Ekman P, Pfeffer MA, Wedel H, et al. Risk factors, mortality trends and cardiovasuclar diseases in people with Type 1 diabetes and controls: A Swedish observational cohort study. Lancet Reg Health Eur. 2022;21:100469. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100469.","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"338_CR109","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1464-5491.2008.02640.x","volume":"26","author":"U Bulugahapitiya","year":"2009","unstructured":"Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26(2):142\u20138. https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02640.x.","journal-title":"Diabet Med"},{"issue":"1","key":"338_CR110","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12933-020-01137-x","volume":"19","author":"N Tecce","year":"2020","unstructured":"Tecce N, Masulli M, Lupoli R, Della Pepa G, Bozzetto L, Palmisano L, et al. Evaluation of cardiovascular risk in adults with type 1 diabetes: poor concordance between the 2019 ESC risk classification and 10-year cardiovascular risk prediction according to the Steno Type 1 Risk Engine. Cardiovasc Diabetol. 2020;19(1):166. https:\/\/doi.org\/10.1186\/s12933-020-01137-x.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"338_CR111","doi-asserted-by":"publisher","first-page":"e3090","DOI":"10.1002\/dmrr.3090","volume":"35","author":"NSR Lan","year":"2019","unstructured":"Lan NSR, Fegan PG, Yeap BB, Bell DA, Watts GF. Dyslipidaemia in adults with type 1 diabetes-when to treat? Diabetes Metab Res Rev. 2019;35(1):e3090. https:\/\/doi.org\/10.1002\/dmrr.3090.","journal-title":"Diabetes Metab Res Rev"},{"issue":"23","key":"338_CR112","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/nejm199306103282306","volume":"328","author":"DM Nathan","year":"1993","unstructured":"Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328(23):1676\u201385. https:\/\/doi.org\/10.1056\/nejm199306103282306.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"338_CR113","first-page":"57","volume":"39","author":"A Imms","year":"2010","unstructured":"Imms A, Quinn S, Nelson M. General practitioners\u2019 use of cardiovascular risk calculators. Aust Fam Physician. 2010;39(1\u20132):57\u201360.","journal-title":"Aust Fam Physician"},{"issue":"11","key":"338_CR114","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","volume":"133","author":"D Vistisen","year":"2016","unstructured":"Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus. Circulation. 2016;133(11):1058\u201366. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018844.","journal-title":"Circulation"},{"issue":"4","key":"338_CR115","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2337\/dc20-2586","volume":"44","author":"D Vistisen","year":"2021","unstructured":"Vistisen D, Andersen GS, Hulman A, McGurnaghan SJ, Colhoun HM, Henriksen JE, et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care. 2021;44(4):901\u20137. https:\/\/doi.org\/10.2337\/dc20-2586.","journal-title":"Diabetes Care"},{"key":"338_CR116","doi-asserted-by":"publisher","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. https:\/\/doi.org\/10.1136\/bmj.j.2099.","DOI":"10.1136\/bmj.j.2099"},{"issue":"10","key":"338_CR117","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/j.1464-5491.2011.03342.x","volume":"28","author":"J Cederholm","year":"2011","unstructured":"Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbj\u00f6rnsdottir S, Register, obotSND. A new model for 5-year risk of cardiovascular disease in Type\u20031 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med. 2011;28(10):1213\u201320. https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03342.x.","journal-title":"Diabet Med"},{"issue":"9","key":"338_CR118","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s00125-021-05478-4","volume":"64","author":"SJ McGurnaghan","year":"2021","unstructured":"McGurnaghan SJ, McKeigue PM, Read SH, Franzen S, Svensson A-M, Colombo M, et al. Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia. 2021;64(9):2001\u201311. https:\/\/doi.org\/10.1007\/s00125-021-05478-4.","journal-title":"Diabetologia"},{"issue":"6","key":"338_CR119","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1111\/dom.15531","volume":"26","author":"MAG Helmink","year":"2024","unstructured":"Helmink MAG, Hageman SHJ, Eliasson B, Sattar N, Visseren FLJ, Dorresteijn JAN, et al. Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model. Diabetes Obes Metab. 2024;26(6):2229\u201338. https:\/\/doi.org\/10.1111\/dom.15531.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"338_CR120","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12933-024-02185-3","volume":"23","author":"TME Davis","year":"2024","unstructured":"Davis TME, Tan E, Davis WA. Prevalence and prognostic significance of cardiac autonomic neuropathy in community-based people with type 2 diabetes: the Fremantle Diabetes Study Phase II. Cardiovasc Diabetol. 2024;23(1):102. https:\/\/doi.org\/10.1186\/s12933-024-02185-3.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"338_CR121","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.amjcard.2007.10.019","volume":"101","author":"X Yang","year":"2008","unstructured":"Yang X, So W-Y, Kong APS, Ma RCW, Ko GTC, Ho C-S, et al. Development and Validation of a Total Coronary Heart Disease Risk Score in Type 2 Diabetes Mellitus. Am J Cardiol. 2008;101(5):596\u2013601. https:\/\/doi.org\/10.1016\/j.amjcard.2007.10.019.","journal-title":"Am J Cardiol"},{"issue":"10","key":"338_CR122","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/s2213-8587(17)30221-8","volume":"5","author":"S Basu","year":"2017","unstructured":"Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol. 2017;5(10):788\u201398. https:\/\/doi.org\/10.1016\/s2213-8587(17)30221-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"338_CR123","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925\u201333. https:\/\/doi.org\/10.1007\/s00125-013-2940-y.","journal-title":"Diabetologia"},{"issue":"1","key":"338_CR124","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/imj.16599","volume":"55","author":"S Wimalarathne","year":"2025","unstructured":"Wimalarathne S, Goh YA, Fegan PG, Yeap BB, Lan NSR. Comparison of cardiovascular risk prediction in type 1 diabetes: an Australian viewpoint. Intern Med J. 2025;55(1):134\u20138. https:\/\/doi.org\/10.1111\/imj.16599.","journal-title":"Intern Med J"},{"issue":"5","key":"338_CR125","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/imj.16089","volume":"53","author":"K Hughes","year":"2023","unstructured":"Hughes K, Lan NSR, Fegan PG. Cardiovascular risk stratification in type 1 diabetes: do risk calculators and guidelines align? Intern Med J. 2023;53(5):879\u201381. https:\/\/doi.org\/10.1111\/imj.16089.","journal-title":"Intern Med J"},{"issue":"8","key":"338_CR126","doi-asserted-by":"publisher","first-page":"108557","DOI":"10.1016\/j.jdiacomp.2023.108557","volume":"37","author":"YA Goh","year":"2023","unstructured":"Goh YA, Lan NSR, Linn K, Wood C, Gupta A, Yeap BB, et al. Comparison of coronary artery calcium score and cardiovascular risk-stratification by European Society of Cardiology Guidelines and Steno Type 1 Risk Engine in statin-na\u00efve adults with type 1 diabetes. J Diabetes Complications. 2023;37(8):108557. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108557.","journal-title":"J Diabetes Complications"},{"issue":"9786","key":"338_CR127","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/s0140-6736(11)60471-6","volume":"378","author":"M Lind","year":"2011","unstructured":"Lind M, Bounias I, Olsson M, Gudbj\u00f6rnsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011;378(9786):140\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(11)60471-6.","journal-title":"Lancet"},{"issue":"11","key":"338_CR128","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/s2213-8587(15)00292-2","volume":"3","author":"A Rosengren","year":"2015","unstructured":"Rosengren A, Vestberg D, Svensson AM, Kosiborod M, Clements M, Rawshani A, et al. Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3(11):876\u201385. https:\/\/doi.org\/10.1016\/s2213-8587(15)00292-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"338_CR129","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1530\/eje-19-1015","volume":"182","author":"R R\u00f8rth","year":"2020","unstructured":"R\u00f8rth R, J\u00f8rgensen PG, Andersen HU, Christoffersen C, G\u00f8tze JP, K\u00f8ber L, et al. Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: the Thousand & 1 Study. Eur J Endocrinol. 2020;182(5):481\u20138. https:\/\/doi.org\/10.1530\/eje-19-1015.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"338_CR130","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2337\/dc20-0359","volume":"43","author":"T Costacou","year":"2020","unstructured":"Costacou T, Saenger AK, Orchard TJ. High-Sensitivity Cardiac Troponin-T and N-Terminal Prohormone of B-Type Natriuretic Peptide in Relation to Cardiovascular Outcomes in Type 1 Diabetes. Diabetes Care. 2020;43(9):2199\u2013207. https:\/\/doi.org\/10.2337\/dc20-0359.","journal-title":"Diabetes Care"},{"issue":"1","key":"338_CR131","doi-asserted-by":"publisher","first-page":"109235","DOI":"10.1016\/j.jdiacomp.2025.109235","volume":"40","author":"WB Horton","year":"2026","unstructured":"Horton WB, Mosslemi M, Valenzuela MS, Miller RG, Orchard TJ, Costacou T. Baseline NT-proBNP and incident heart failure in type 1 diabetes: The epidemiology of diabetes complications study. J Diabetes Complications. 2026;40(1):109235. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109235.","journal-title":"J Diabetes Complications"},{"issue":"2","key":"338_CR132","doi-asserted-by":"publisher","first-page":"e14455","DOI":"10.1111\/dme.14455","volume":"38","author":"E Maddaloni","year":"2021","unstructured":"Maddaloni E, Moretti C, Del Toro R, Sterpetti S, Ievolella MV, Arnesano G, et al. Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: A cross-sectional study. Diabet Med. 2021;38(2):e14455. https:\/\/doi.org\/10.1111\/dme.14455.","journal-title":"Diabet Med"},{"issue":"7","key":"338_CR133","doi-asserted-by":"publisher","first-page":"244","DOI":"10.31083\/j.rcm2507244","volume":"25","author":"X Huang","year":"2024","unstructured":"Huang X, Bao Y, Wang J, Tian L. Prevalence and Risk Factors of Cardiovascular Autonomic Neuropathy in Individuals with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med. 2024;25(7):244. https:\/\/doi.org\/10.31083\/j.rcm2507244.","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"338_CR134","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12933-025-02856-9","volume":"24","author":"BH Braffett","year":"2025","unstructured":"Braffett BH, El ghormli L, Martin C, White NH, Hirsch IB, Bantle A, et al. Cardiovascular autonomic neuropathy defined by indices of heart rate variability is associated with cardiovascular disease: a longitudinal cohort study of participants with type 1 diabetes. Cardiovasc Diabetol. 2025;24(1):334\u20139. https:\/\/doi.org\/10.1186\/s12933-025-02856-9.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"338_CR135","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12933-025-02635-6","volume":"24","author":"R Risi","year":"2025","unstructured":"Risi R, Amendolara R, Pantano AL, Fassino V, D\u2019Onofrio L, Coraggio L, et al. Cardiac autonomic neuropathy is associated with ectopic fat distribution in autoimmune but not in type 2 diabetes. Cardiovasc Diabetol. 2025;24(1):74. https:\/\/doi.org\/10.1186\/s12933-025-02635-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"338_CR136","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","volume":"40","author":"R Pop-Busui","year":"2017","unstructured":"Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136\u201354. https:\/\/doi.org\/10.2337\/dc16-2042.","journal-title":"Diabetes Care"},{"issue":"4","key":"338_CR137","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jacc.2012.10.028","volume":"61","author":"R Pop-Busui","year":"2013","unstructured":"Pop-Busui R, Cleary PA, Braffett BH, Martin CL, Herman WH, Low PA, et al. Association Between Cardiovascular Autonomic Neuropathy and Left Ventricular Dysfunction. J Am Coll Cardiol. 2013;61(4):447\u201354. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.028.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"338_CR138","doi-asserted-by":"publisher","first-page":"109290","DOI":"10.1016\/j.jdiacomp.2026.109290","volume":"40","author":"M Ziori","year":"2026","unstructured":"Ziori M, Tentolouris A, Eleftheriadou I, Voudouri A, Simati S, Aissopou E, et al. Corneal confocal microscopy and cardiac autonomic neuropathy in individuals with type 1 diabetes mellitus. J Diabetes Complications. 2026;40(4):109290. https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109290.","journal-title":"J Diabetes Complications"},{"issue":"2","key":"338_CR139","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/dme.12583","volume":"32","author":"E Maddaloni","year":"2015","unstructured":"Maddaloni E, Sabatino F, Del Toro R, Crugliano S, Grande S, Lauria Pantano A, et al. In vivo corneal confocal microscopy as a novel non-invasive tool to investigate cardiac autonomic neuropathy in Type 1 diabetes. Diabet Med. 2015;32(2):262\u20136. https:\/\/doi.org\/10.1111\/dme.12583.","journal-title":"Diabet Med"},{"issue":"12","key":"338_CR140","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s00125-024-06242-0","volume":"67","author":"A Eleftheriadou","year":"2024","unstructured":"Eleftheriadou A, Spallone V, Tahrani AA, Alam U. Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management. Diabetologia. 2024;67(12):2611\u201325. https:\/\/doi.org\/10.1007\/s00125-024-06242-0.","journal-title":"Diabetologia"},{"issue":"9","key":"338_CR141","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1111\/j.1464-5491.2012.03719.x","volume":"29","author":"JW Sacre","year":"2012","unstructured":"Sacre JW, Jellis CL, Coombes JS, Marwick TH. Diagnostic accuracy of heart-rate recovery after exercise in the assessment of diabetic cardiac autonomic neuropathy. Diabet Med. 2012;29(9):e312\u201320. https:\/\/doi.org\/10.1111\/j.1464-5491.2012.03719.x.","journal-title":"Diabet Med"},{"issue":"Suppl 1","key":"338_CR142","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","volume":"47","author":"10. Cardiovascular Disease and Risk Management","year":"2024","unstructured":"10. Cardiovascular Disease and Risk Management. Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S179\u2013218. https:\/\/doi.org\/10.2337\/dc24-S010.","journal-title":"Diabetes Care"},{"key":"338_CR143","doi-asserted-by":"publisher","first-page":"112121","DOI":"10.1016\/j.diabres.2025.112121","volume":"223","author":"E Zomer","year":"2025","unstructured":"Zomer E, Talic S, Pourghaderi AR, Earnest A, Quigley M, Gasevic D, et al. The management of cardiovascular risk in people with diabetes: Insights from an audit of health services providing diabetes care. Diabetes Res Clin Pract. 2025;223:112121. https:\/\/doi.org\/10.1016\/j.diabres.2025.112121.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7 Pt 2","key":"338_CR144","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jcmg.2019.01.014","volume":"12","author":"M Budoff","year":"2019","unstructured":"Budoff M, Backlund JC, Bluemke DA, Polak J, Bebu I, Schade D, et al. The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes: The DCCT\/EDIC Trials. JACC Cardiovasc Imaging. 2019;12(7 Pt 2):1341\u20139. https:\/\/doi.org\/10.1016\/j.jcmg.2019.01.014.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"338_CR145","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jacl.2020.12.005","volume":"15","author":"CE Orringer","year":"2021","unstructured":"Orringer CE, Blaha MJ, Blankstein R, Budoff MJ, Goldberg RB, Gill EA, et al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J Clin Lipidol. 2021;15(1):33\u201360. https:\/\/doi.org\/10.1016\/j.jacl.2020.12.005.","journal-title":"J Clin Lipidol"},{"issue":"13","key":"338_CR146","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1161\/cir.0000000000000034","volume":"130","author":"SD de Ferranti","year":"2014","unstructured":"de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014;130(13):1110\u201330. https:\/\/doi.org\/10.1161\/cir.0000000000000034.","journal-title":"Circulation"},{"key":"338_CR147","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-015-0285-1","volume":"14","author":"P Wang","year":"2015","unstructured":"Wang P, Huang R, Lu S, Xia W, Sun H, Sun J, et al. HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovasc Diabetol. 2015;14:124. https:\/\/doi.org\/10.1186\/s12933-015-0285-1.","journal-title":"Cardiovasc Diabetol"},{"key":"338_CR148","doi-asserted-by":"publisher","unstructured":"Gajjar A, Raju AK, Gajjar A, Menon M, Shah SAY, Dani S, et al. SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome. Biomedicines. 2025;13(8). https:\/\/doi.org\/10.3390\/biomedicines13081924.","DOI":"10.3390\/biomedicines13081924"},{"issue":"10","key":"338_CR149","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","volume":"66","author":"M Anson","year":"2023","unstructured":"Anson M, Zhao SS, Austin P, Ibarburu GH, Malik RA, Alam U. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. Diabetologia. 2023;66(10):1869\u201381. https:\/\/doi.org\/10.1007\/s00125-023-05975-8.","journal-title":"Diabetologia"},{"issue":"16","key":"338_CR150","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1161\/CIRCULATIONAHA.123.064041","volume":"147","author":"F Rodriguez","year":"2023","unstructured":"Rodriguez F, Khera A. How Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention. Circulation. 2023;147(16):1204\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064041.","journal-title":"Circulation"},{"key":"338_CR151","doi-asserted-by":"publisher","unstructured":"Barrios V, Pint\u00f3 X, Escobar C, Varona JF, G\u00e1mez JM. Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study. J Clin Med. 2023;12(9). https:\/\/doi.org\/10.3390\/jcm12093187.","DOI":"10.3390\/jcm12093187"},{"key":"338_CR152","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2020.12.013","volume":"319","author":"D Atar","year":"2021","unstructured":"Atar D, Jukema JW, Molemans B, Taub PR, Goto S, Mach F, et al. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis. 2021;319:51\u201361. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.12.013.","journal-title":"Atherosclerosis"},{"issue":"1","key":"338_CR153","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/xce.0000000000000166","volume":"8","author":"H Mamet","year":"2019","unstructured":"Mamet H, Petrie MC, Rocchiccioli P. Type 1 diabetes mellitus and coronary revascularization. Cardiovasc Endocrinol Metab. 2019;8(1):35\u20138. https:\/\/doi.org\/10.1097\/xce.0000000000000166.","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"12","key":"338_CR154","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.jacc.2017.07.744","volume":"70","author":"T Nystr\u00f6m","year":"2017","unstructured":"Nystr\u00f6m T, Sartipy U, Franz\u00e9n S, Eliasson B, Gudbj\u00f6rnsdottir S, Miftaraj M, et al. PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease. J Am Coll Cardiol. 2017;70(12):1441\u201351. https:\/\/doi.org\/10.1016\/j.jacc.2017.07.744.","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"338_CR155","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(39):4043\u2013140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192.","journal-title":"Eur Heart J"},{"issue":"22","key":"338_CR156","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1161\/CIRCULATIONAHA.120.045465","volume":"142","author":"D Capodanno","year":"2020","unstructured":"Capodanno D, Angiolillo DJ. Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. Circulation. 2020;142(22):2172\u201388. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.045465.","journal-title":"Circulation"},{"issue":"10","key":"338_CR157","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.hlc.2018.06.1042","volume":"27","author":"JJ Atherton","year":"2018","unstructured":"Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, MacDonald PS, Hopper I, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung Circ. 2018;27(10):1123\u2013208. https:\/\/doi.org\/10.1016\/j.hlc.2018.06.1042.","journal-title":"Heart Lung Circ"},{"issue":"4","key":"338_CR158","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00592-013-0455-0","volume":"50","author":"E Konduracka","year":"2013","unstructured":"Konduracka E, Cieslik G, Galicka-Latala D, Rostoff P, Pietrucha A, Latacz P, et al. Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. Acta Diabetol. 2013;50(4):597\u2013606. https:\/\/doi.org\/10.1007\/s00592-013-0455-0.","journal-title":"Acta Diabetol"},{"issue":"4","key":"338_CR159","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5694\/mja2.51656","volume":"217","author":"AP Sindone","year":"2022","unstructured":"Sindone AP, De Pasquale C, Amerena J, Burdeniuk C, Chan A, Coats A, et al. Consensus statement on the current pharmacological prevention and management of heart failure. Med J Aust. 2022;217(4):212\u20137. https:\/\/doi.org\/10.5694\/mja2.51656.","journal-title":"Med J Aust"},{"issue":"2","key":"338_CR160","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.hlc.2025.09.019","volume":"35","author":"AP Sindone","year":"2026","unstructured":"Sindone AP, Amerena J, De Pasquale CG, Chan AWP, Gan GCH, Rao SD, et al. Consensus Statement on Optimisation of Patient Care After Hospitalisation for Acute Heart Failure. Heart Lung Circ. 2026;35(2):157\u201370. https:\/\/doi.org\/10.1016\/j.hlc.2025.09.019.","journal-title":"Heart Lung Circ"},{"issue":"1","key":"338_CR161","doi-asserted-by":"publisher","first-page":"e7460084","DOI":"10.1155\/jdr\/7460084","volume":"2026","author":"MS Hussain","year":"2026","unstructured":"Hussain MS, Iyer S, Liew YJ, Win ML, McCrimmon RJ, Lang CC, et al. Heart Failure in Type 1 vs. Type 2 Diabetes Mellitus: Shared Pathways, Distinct Challenges. J Diabetes Res. 2026;2026(1):e7460084. https:\/\/doi.org\/10.1155\/jdr\/7460084.","journal-title":"J Diabetes Res"},{"issue":"1","key":"338_CR162","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s13300-019-00728-6","volume":"11","author":"M Evans","year":"2020","unstructured":"Evans M, Hicks D, Patel D, Patel V, McEwan P, Dashora U. Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes. Diabetes Ther. 2020;11(1):37\u201352. https:\/\/doi.org\/10.1007\/s13300-019-00728-6.","journal-title":"Diabetes Ther"},{"issue":"3","key":"338_CR163","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1161\/circulationaha.124.069695","volume":"151","author":"IR Mordi","year":"2025","unstructured":"Mordi IR, McCrimmon RJ, Lang CC. SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap. Circulation. 2025;151(3):199\u2013201. https:\/\/doi.org\/10.1161\/circulationaha.124.069695.","journal-title":"Circulation"},{"issue":"7","key":"338_CR164","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.3649","volume":"27","author":"JH Butt","year":"2025","unstructured":"Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, et al. Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail. 2025;27(7):1326\u201341. https:\/\/doi.org\/10.1002\/ejhf.3649.","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"338_CR165","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1161\/circulationaha.108.837369","volume":"119","author":"R Pop-Busui","year":"2009","unstructured":"Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, et al. Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus. Circulation. 2009;119(22):2886\u201393. https:\/\/doi.org\/10.1161\/circulationaha.108.837369.","journal-title":"Circulation"},{"issue":"12","key":"338_CR166","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.3390\/biomedicines10123258","volume":"10","author":"SZ Sudo","year":"2022","unstructured":"Sudo SZ, Montagnoli TL, Rocha BS, Santos AD, de S\u00e1 MPL, Zapata-Sudo G. Diabetes-Induced Cardiac Autonomic Neuropathy: Impact on Heart Function and Prognosis. Biomedicines. 2022;10(12):3258. https:\/\/doi.org\/10.3390\/biomedicines10123258.","journal-title":"Biomedicines"},{"key":"338_CR167","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.70316","author":"AKH Ma","year":"2026","unstructured":"Ma AKH, Tam CHT, Luk AOY, Wu H, Fan Y, Lau ESH, et al. Validation of the ST1RE risk engine in Chinese with type 1 diabetes and comparison with the JADE, RECODe, and UKPDS risk scores. J Diabetes Invest. 2026;n\/a(n\/a). https:\/\/doi.org\/10.1111\/jdi.70316.","journal-title":"J Diabetes Invest"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-026-00338-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:02:58Z","timestamp":1789941778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-026-00338-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":167,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1186\/s40842-026-00338-9","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NSRL has received research funding from Amgen and Sanofi (as part of a Clinical Fellowship in Endocrinology and Diabetes); education support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Seqirus, Eli Lilly, Novartis, Novo Nordisk and Pfizer; speaker honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, CSL Seqirus, Eli Lilly, Menarini, Novartis, Novo Nordisk and Sanofi; and has participated in advisory boards for Eli Lilly. JTH has received honorarium from Atheneum and royalties from MedicineToday with all remuneration paid to his institution. Unrelated to this project, AS has received honoraria, speaker fees, consultancy fees, travel support, is a member of advisory boards or has appeared on expert panels for: Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL, Edwards, Eli Lilly, Glaxo Smith Kline, Impedimed, Menarini, Merck Sharp and Dohm, Moderna, National Cardiac Australia, Novartis, Novo Nordisk, Otsuka, Pfizer, Pharmacosmos, Phebra, Roche, Sanofi, Servier, Viatris. Unrelated to this project AJJ has received lecture fees from CSL Seqirus and is on advisory boards for Abbott Diabetes (Australia) and GSK, and is on (honourary) advisory boards for the International Diabetes Federation, Insulin For Life, Diabetes Australia and the National Heart Foundation. AJJ has received peer-reviewed grants from the NHMRC, MRFF, JDRF \/ Breakthrough T1D and trial support from Medtronic, YpsoMed, Abbott and Insulet.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"63"}}